These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 20645037)

  • 1. S100A1: a multifaceted therapeutic target in cardiovascular disease.
    Rohde D; Ritterhoff J; Voelkers M; Katus HA; Parker TG; Most P
    J Cardiovasc Transl Res; 2010 Oct; 3(5):525-37. PubMed ID: 20645037
    [TBL] [Abstract][Full Text] [Related]  

  • 2. S100A1 in cardiovascular health and disease: closing the gap between basic science and clinical therapy.
    Kraus C; Rohde D; Weidenhammer C; Qiu G; Pleger ST; Voelkers M; Boerries M; Remppis A; Katus HA; Most P
    J Mol Cell Cardiol; 2009 Oct; 47(4):445-55. PubMed ID: 19538970
    [TBL] [Abstract][Full Text] [Related]  

  • 3. S100A1: a regulator of striated muscle sarcoplasmic reticulum Ca2+ handling, sarcomeric, and mitochondrial function.
    Völkers M; Rohde D; Goodman C; Most P
    J Biomed Biotechnol; 2010; 2010():178614. PubMed ID: 20368797
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cardiac AAV9-S100A1 gene therapy rescues post-ischemic heart failure in a preclinical large animal model.
    Pleger ST; Shan C; Ksienzyk J; Bekeredjian R; Boekstegers P; Hinkel R; Schinkel S; Leuchs B; Ludwig J; Qiu G; Weber C; Raake P; Koch WJ; Katus HA; Müller OJ; Most P
    Sci Transl Med; 2011 Jul; 3(92):92ra64. PubMed ID: 21775667
    [TBL] [Abstract][Full Text] [Related]  

  • 5. S100A1: a pluripotent regulator of cardiac and vascular function.
    Desjardins JF; Teichert-Kuliszewska K; Parker T
    Can J Cardiol; 2010 Mar; 26 Suppl A():9A-12A. PubMed ID: 20386753
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cardiac S100A1 protein levels determine contractile performance and propensity toward heart failure after myocardial infarction.
    Most P; Seifert H; Gao E; Funakoshi H; Völkers M; Heierhorst J; Remppis A; Pleger ST; DeGeorge BR; Eckhart AD; Feldman AM; Koch WJ
    Circulation; 2006 Sep; 114(12):1258-68. PubMed ID: 16952982
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cardiomyocytes, endothelial cells and cardiac fibroblasts: S100A1's triple action in cardiovascular pathophysiology.
    Rohde D; Busch M; Volkert A; Ritterhoff J; Katus HA; Peppel K; Most P
    Future Cardiol; 2015 May; 11(3):309-21. PubMed ID: 26021637
    [TBL] [Abstract][Full Text] [Related]  

  • 8. S100A1: a novel inotropic regulator of cardiac performance. Transition from molecular physiology to pathophysiological relevance.
    Most P; Remppis A; Pleger ST; Katus HA; Koch WJ
    Am J Physiol Regul Integr Comp Physiol; 2007 Aug; 293(2):R568-77. PubMed ID: 17459908
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Endothelial S100A1 modulates vascular function via nitric oxide.
    Pleger ST; Harris DM; Shan C; Vinge LE; Chuprun JK; Berzins B; Pleger W; Druckman C; Völkers M; Heierhorst J; Øie E; Remppis A; Katus HA; Scalia R; Eckhart AD; Koch WJ; Most P
    Circ Res; 2008 Apr; 102(7):786-94. PubMed ID: 18292599
    [TBL] [Abstract][Full Text] [Related]  

  • 10. S100A1: a major player in cardiovascular performance.
    Duarte-Costa S; Castro-Ferreira R; Neves JS; Leite-Moreira AF
    Physiol Res; 2014; 63(6):669-81. PubMed ID: 25157660
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ca2+ -dependent interaction of S100A1 with F1-ATPase leads to an increased ATP content in cardiomyocytes.
    Boerries M; Most P; Gledhill JR; Walker JE; Katus HA; Koch WJ; Aebi U; Schoenenberger CA
    Mol Cell Biol; 2007 Jun; 27(12):4365-73. PubMed ID: 17438143
    [TBL] [Abstract][Full Text] [Related]  

  • 12. S100A1 gene therapy for heart failure: a novel strategy on the verge of clinical trials.
    Rohde D; Brinks H; Ritterhoff J; Qui G; Ren S; Most P
    J Mol Cell Cardiol; 2011 May; 50(5):777-84. PubMed ID: 20732326
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cardiac adenoviral S100A1 gene delivery rescues failing myocardium.
    Most P; Pleger ST; Völkers M; Heidt B; Boerries M; Weichenhan D; Löffler E; Janssen PM; Eckhart AD; Martini J; Williams ML; Katus HA; Remppis A; Koch WJ
    J Clin Invest; 2004 Dec; 114(11):1550-63. PubMed ID: 15578088
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Post-translational S-nitrosylation is an endogenous factor fine tuning the properties of human S100A1 protein.
    Lenarčič Živković M; Zaręba-Kozioł M; Zhukova L; Poznański J; Zhukov I; Wysłouch-Cieszyńska A
    J Biol Chem; 2012 Nov; 287(48):40457-70. PubMed ID: 22989881
    [TBL] [Abstract][Full Text] [Related]  

  • 15. S100A1 genetically targeted therapy reverses dysfunction of human failing cardiomyocytes.
    Brinks H; Rohde D; Voelkers M; Qiu G; Pleger ST; Herzog N; Rabinowitz J; Ruhparwar A; Silvestry S; Lerchenmüller C; Mather PJ; Eckhart AD; Katus HA; Carrel T; Koch WJ; Most P
    J Am Coll Cardiol; 2011 Aug; 58(9):966-73. PubMed ID: 21851887
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting S100A1 in heart failure.
    Ritterhoff J; Most P
    Gene Ther; 2012 Jun; 19(6):613-21. PubMed ID: 22336719
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapeutic safety of high myocardial expression levels of the molecular inotrope S100A1 in a preclinical heart failure model.
    Weber C; Neacsu I; Krautz B; Schlegel P; Sauer S; Raake P; Ritterhoff J; Jungmann A; Remppis AB; Stangassinger M; Koch WJ; Katus HA; Müller OJ; Most P; Pleger ST
    Gene Ther; 2014 Feb; 21(2):131-8. PubMed ID: 24305416
    [TBL] [Abstract][Full Text] [Related]  

  • 18. S100A1 increases the gain of excitation-contraction coupling in isolated rabbit ventricular cardiomyocytes.
    Kettlewell S; Most P; Currie S; Koch WJ; Smith GL
    J Mol Cell Cardiol; 2005 Dec; 39(6):900-10. PubMed ID: 16236309
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Transgenic overexpression of the Ca2+-binding protein S100A1 in the heart leads to increased in vivo myocardial contractile performance.
    Most P; Remppis A; Pleger ST; Löffler E; Ehlermann P; Bernotat J; Kleuss C; Heierhorst J; Ruiz P; Witt H; Karczewski P; Mao L; Rockman HA; Duncan SJ; Katus HA; Koch WJ
    J Biol Chem; 2003 Sep; 278(36):33809-17. PubMed ID: 12777394
    [TBL] [Abstract][Full Text] [Related]  

  • 20. S100A1 DNA-based Inotropic Therapy Protects Against Proarrhythmogenic Ryanodine Receptor 2 Dysfunction.
    Ritterhoff J; Völkers M; Seitz A; Spaich K; Gao E; Peppel K; Pleger ST; Zimmermann WH; Friedrich O; Fink RHA; Koch WJ; Katus HA; Most P
    Mol Ther; 2015 Aug; 23(8):1320-1330. PubMed ID: 26005840
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.